Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics Inc
(NQ:
KYMR
)
48.49
-1.26 (-2.52%)
Streaming Delayed Price
Updated: 1:14 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kymera Therapeutics Inc
< Previous
1
2
3
Next >
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
November 13, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
November 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
October 27, 2023
The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
October 16, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
September 18, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 28, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
August 03, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
June 22, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
June 09, 2023
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conference
June 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
May 22, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
May 19, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
May 18, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
May 04, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
April 11, 2023
Company also presenting at upcoming investor conferences
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
March 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
February 23, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
February 01, 2023
Company also presenting at upcoming investor conferences
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
X-Chem and Kymera Expand Existing Partnership
January 31, 2023
From
X-Chem
Via
Business Wire
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
January 10, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
January 04, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
December 14, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
December 12, 2022
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.